Learn more and donate: http://www.maps.org/
Amanda Feilding: From Taboo to Treatment – The Evolution of Psychedelic Medicine
2017 Psychedelic Science Conference
http://psychedelicscience.org/
A six-day global gathering of the international scientific community in Oakland, California to explore new research into the benefits and risks of MDMA, LSD, psilocybin, ayahuasca, ketamine, ibogaine, medical marijuana, and more.
source
Learn more and donate: http://www.maps.org/
PANEL:
Geoff Noller, PhD, and Thomas Kingsley Brown, PhD
moderated by Clare Wilkins
Insights from Contemporary
Ibogaine Research for Addiction
2017 Psychedelic Science Conference
http://psychedelicscience.org/
A six-day global gathering of the international scientific community in Oakland, California to explore new research into the benefits and risks of MDMA, LSD, psilocybin, ayahuasca, ketamine, ibogaine, medical marijuana, and more.
source
Learn more and donate: http://www.maps.org/
Ignacio Carrera, PhD
Ibogaine and Neurotrophic Factors: GDNF, BDNF,
and NGF Releasing Properties of Ibogaine and Activity
of Novel Ibogaine Analogues
2017 Psychedelic Science Conference
http://psychedelicscience.org/
A six-day global gathering of the international scientific community in Oakland, California to explore new research into the benefits and risks of MDMA, LSD, psilocybin, ayahuasca, ketamine, ibogaine, medical marijuana, and more.
source
Tyson and Walt discuss Googles decision to not allow some clinics to advertise Ibogaine Treatment saying we are promoting recreational drug use. This makes getting the message out to people in need much more difficult. Also, caller Allen Brush talks about the challenges of finding support from his family and his church to do Ibogaine treatment. We discuss the cultural barriers to traditional and alternative treatments like ...